According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

## Ivermectin (3.5%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.3	06.04.2024	9374193-00013	Date of first issue: 27.08.2021

### **SECTION 1:** Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Ivermectin (3.5%) Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture		Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Walton Manor, Walton MK7 7AJ Milton Keynes - United Kingdom
	Telephone	:	+1-908-740-4000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

### **1.4 Emergency telephone number**

+1-908-423-6000

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

# Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Acute toxicity, Category 4 Specific target organ toxicity - single ex- posure, Category 2	H302: Harmful if swallowed. H371: May cause damage to organs.
Specific target organ toxicity - repeated exposure, Category 2 Short-term (acute) aquatic hazard, Cate-	H373: May cause damage to organs through pro- longed or repeated exposure. H400: Very toxic to aquatic life.
gory 1 Long-term (chronic) aquatic hazard, Cat- egory 1	H410: Very toxic to aquatic life with long lasting effects.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.3	06.04.2024	9374193-00013	Date of first issue: 27.08.2021

### 2.2 Label elements

## Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms :			! ***
Signal word :	١	Warning	• •
Hazard statements :	ŀ	H302 H371 H373 H410	Harmful if swallowed. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.
Precautionary statements :	F	Prevention P264 P270 P273	Wash skin thoroughly after handling. Do not eat, drink or smoke when using this prod- uct. Avoid release to the environment.
	F	<b>Response:</b> P301 + P31 P308 + P31 P391	<ul> <li>2 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.</li> <li>1 IF exposed or concerned: Call a POISON CENTER/ doctor. Collect spillage.</li> </ul>

Hazardous components which must be listed on the label: Ivermectin

### **Additional Labelling**

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 1.42 %

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
	Registration number		

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024	SDS Number: 9374193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
lverm	nectin	70288-86-7 274-536-0	Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000	>= 2.5 - < 10
2,6-D	i-tert-butyl-p-cresol	128-37-0 204-881-4	Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	>= 0.25 - < 1

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.



Version 5.3	Revision Date: 06.04.2024		0S Number: 74193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
If swallowed		:	If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.		
4.2 Mos	st important symptoms ar	nd e	effects, both acute	e and delayed	
Ris	sks	:	Harmful if swallov May cause dama May cause dama exposure.		
4.3 Ind	ication of any immediate	meo	dical attention and	d special treatment needed	
	eatment	:		ically and supportively.	
SECTI	ON 5: Firefighting meas	sur	es		
5.1 Ext	inguishing media				
	itable extinguishing media	a : Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical			
	suitable extinguishing edia	:	None known.		
5 2 Sne	ecial hazards arising from	the	substance or mi	vture	
Sp		:		bustion products may be a hazard to health.	
Ha uc	zardous combustion prod- ts	:	Carbon oxides Metal oxides		
53 Adv	vice for firefighters				
Sp	ecial protective equipment firefighters	:		e, wear self-contained breathing apparatus. tective equipment.	
Sp od	ecific extinguishing meth- s	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.3	06.04.2024	9374193-00013	Date of first issue: 27.08.2021

### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil

barriers). Retain and dispose of contaminated wash water. If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	<ul> <li>Soak up with inert absorbent material.</li> <li>For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.</li> <li>Clean up remaining materials from spill with suitable absorbent.</li> <li>Local or national regulations may apply to releases and dis-</li> </ul>
	posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

	-	
Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe vapours.
ç		Do not swallow.
		Avoid contact with eyes.
		Avoid prolonged or repeated contact with skin.
		Wash skin thoroughly after handling.
		Handle in accordance with good industrial hygiene and safety
		practice, based on the results of the workplace exposure as- sessment
		Do not eat, drink or smoke when using this product.
		Take care to prevent spills, waste and minimize release to the

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024		DS Number: 374193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021			
Hygiene measures		:	<ul> <li>environment.</li> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.</li> <li>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</li> </ul>				
7.2 Cond	itions for safe storage,	inc	including any incompatibilities				
	uirements for storage s and containers	:	Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.				
Advi	ce on common storage	:	Strong oxidizing a	stances and mixtures			
7.3 Spec	ific end use(s)						

## Specific use(s)

: No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ivermectin	70288-86-7	TWA	30 µg/m3 (OEB 3)	Internal
	Further inform	nation: Skin		
		Wipe limit	300 µg/100 cm2	Internal
2,6-Di-tert-butyl-p- cresol	128-37-0	TWA	10 mg/m3	GB EH40

### **Derived No Effect Level (DNEL):**

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Glycerides, mixed decanoyl and oc- tanoyl	Workers	Inhalation	Long-term systemic effects	177.79 mg/m3
	Workers	Skin contact	Long-term systemic effects	25.21 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	43.84 mg/m3
	Consumers	Skin contact	Long-term systemic effects	12.61 mg/kg bw/day





## Ivermectin (3.5%) Formulation

Ver 5.3	sion Revision Date: 06.04.2024			Date of last issue: 30.09.2023 Date of first issue: 27.08.2021		
		Consumers	Ingestion	<b>e</b> ,	12.61 mg/kg ow/day	
	2,6-Di-tert-butyl-p- cresol	Workers	Inhalation	Long-term systemic 3 effects	3.5 mg/m3	
		Workers	Dermal		).5 mg/kg ow/day	
		Consumers	Inhalation	Long-term systemic ( effects	).86 mg/m3	
		Consumers	Dermal	<b>o</b> ,	).25 mg/kg ow/day	
		Consumers	Ingestion		).25 mg/kg ow/day	

### Predicted No Effect Concentration (PNEC):

Substance name	Environmental Compartment	Value
Glycerides, mixed decanoyl and octanoyl	Oral (Secondary Poisoning)	0.03 mg/kg food
2,6-Di-tert-butyl-p-cresol	Fresh water	0.199 µg/l
	Intermittent use/release	0.02 μg/l
	Marine water	0.02 μg/l
	Sewage treatment plant	0.17 mg/l
	Fresh water sediment	0.0996 mg/kg dry weight (d.w.)
	Marine sediment	0.00996 mg/kg dry weight (d.w.)
	Soil	0.04769 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	8.33 mg/kg food

### 8.2 Exposure controls

### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye/face protection		Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024	SDS Number: 9374193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021				
Skin	and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the to being performed (e.g., sleevelets, apron, gauntlets, dispose suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentia					
Resp	iratory protection	: If adequate loca sure assessme ommended gui	<ul> <li>contaminated clothing.</li> <li>If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.</li> <li>Equipment should conform to BS EN 14387</li> </ul>				
Fi	lter type		culates and organic vapour type (A-P)				

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	an : : :	gel off-white characteristic No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	170 °C
range Flash point	:	237.2 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	0.93 - 0.95
Density	:	No data available
Solubility(ies) Water solubility Partition coefficient: n- octanol/water	:	practically insoluble Not applicable
Auto-ignition temperature	:	No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024		9S Number: 74193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021			
Decomposition temperature		:	No data availabl	e			
Viscosity Viscosity, dynamic		:	: 382 - 384 mPa.s (25 °C)				
Viscosity, kinematic		:	: No data available				
Explosive properties		:	Not explosive				
Oxidizing properties		:	The substance or mixture is not classified as oxidizing.				
<b>9.2 Other information</b> Flammability (liquids)		:	No data availabl	e			
Moleo	cular weight	:	No data availabl	e			
Partic	cle size	:	Not applicable				

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

## 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid :	None known.
-----------------------	-------------

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



	<b>toxicity</b> ul if swallowed.					
Produ	ar in Swanowea.					
	ct:					
	oral toxicity	:	Acute toxicity e Method: Calcul	stimate: 1,511 mg/kg ation method		
Acute	dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method			
Comp	onents:					
lverme	ectin:					
Acute	oral toxicity	:	LD50 (Rat): 50	mg/kg		
			LD50 (Mouse):	25 mg/kg		
			Symptoms: Vo	): > 24 mg/kg Central nervous system miting, Dilatation of the pupil nortality observed at this dose.		
Acute	inhalation toxicity	:	LC50 (Rat): 5.1 Exposure time: Test atmosphe	1 h		
Acute	dermal toxicity	:	LD50 (Rabbit):	406 mg/kg		
			LD50 (Rat): > 6	60 mg/kg		
2,6-Di	-tert-butyl-p-cresol:					
Acute	oral toxicity	:	LD50 (Rat): > 6 Method: OECD	5,000 mg/kg 9 Test Guideline 401		
Acute	dermal toxicity	:	Method: OECD	2,000 mg/kg 9 Test Guideline 402 he substance or mixture has no acute derma		
	orrosion/irritation	ilable	information.			
<u>Comp</u>	onents:					
lverme	ectin:					
Specie Result	es	:	Rabbit No skin irritatio	n		
2,6-Di	-tert-butyl-p-cresol:					
Specie Metho		:	Rabbit OECD Test Gu	ideline 404		

Version

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

SDS Number:



Date of last issue: 30.09.2023

## Ivermectin (3.5%) Formulation

Revision Date:

rsion	Revision Date: 06.04.2024		OS Number: 74193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Resu Rema		:	No skin irritation Based on data	n from similar materials
	ous eye damage/eye			
Not c	lassified based on av	ailable	information.	
Com	ponents:			
lvern	nectin:			
Spec Resu		:	Rabbit Mild eye irritatio	'n
2,6-D	vi-tert-butyl-p-cresol	:		
Spec		:	Rabbit	
Meth Resu		:	OECD Test Gu	
Rema		:	No eye irritatior Based on data	from similar materials
Resp	iratory or skin sens	itisatio	on	
Skin	sensitisation			
-	lassified based on av	ailable	information.	
Resp	piratory sensitisation	า		
-	lassified based on av		information.	
<u>Com</u>	ponents:			
lvern	nectin:			
Expo	sure routes	:	Dermal	
Spec		:	Humans	
Resu	lt	:	Does not cause	skin sensitisation.
2,6-D	i-tert-butyl-p-cresol	:		
Test		:		nsult patch test (HRIPT)
	sure routes	:	Skin contact	
Spec Resu		:	Humans negative	
Germ	n cell mutagenicity			
Not c	lassified based on av	ailable	information.	
Com	ponents:			
lvern	nectin:			
Geno	toxicity in vitro	:	Test Type: Bac Result: negative	terial reverse mutation assay (AMES) e
			thesis in mamm	A damage and repair, unscheduled DNA s alian cells (in vitro) ıman diploid fibroblasts

Test system: human diploid fibroblasts

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024		OS Number: 74193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
			Result: negative		
		Test Type: Mouse Lymphoma Result: negative			
2,6-Di-	tert-butyl-p-cresol:				
-	oxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)	
			Test Type: In vitro Result: negative	o mammalian cell gene mutation test	
			Test Type: Chron Result: negative	nosome aberration test in vitro	
Genoto	oxicity in vivo	:		enicity (in vivo mammalian bone-marrow chromosomal analysis) :: Ingestion	

### Carcinogenicity

Not classified based on available information.

#### **Components:**

Ivermectin: Species Application Route NOAEL Result Remarks	:	Rat Oral 1.5 mg/kg body weight negative Based on data from similar materials
Species Application Route NOAEL Result Remarks	: : : : : : : : : : : : : : : : : : : :	Mouse Oral 2.0 mg/kg body weight negative Based on data from similar materials

### 2,6-Di-tert-butyl-p-cresol:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	22 Months
Result	:	negative

### **Reproductive toxicity**

Not classified based on available information.

#### **Components:**

Ivermectin:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Vers 5.3	sion	Revision Date: 06.04.2024	-	0S Number: 74193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021				
	Effects on fertility		:	<ul> <li>Test Type: Fertility</li> <li>Species: Rat</li> <li>Application Route: Oral</li> <li>Fertility: NOAEL: 0.6 mg/kg body weight</li> <li>Result: Animal testing did not show any effects on fertility.</li> </ul>					
	Effects on foetal develop- ment			Result: Teratogen					
				Result: Embryoto: spring were detect	: Oral oxicity: LOAEL: 0.4 mg/kg body weight xic effects and adverse effects on the off-				
	2.6-Di-	tert-butyl-p-cresol:							
	•	on fertility	:	Test Type: Two-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion				
	Effects ment	on foetal develop-	:	Test Type: Embry Species: Rat Application Route Result: negative	ro-foetal development : Ingestion				
		- single exposure							
		use damage to organs	•						
	Compo	onents:							
	Iverme		_	Control					
	Target Assess	Organs ment	:	Central nervous s Causes damage t					

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

ersion 3	Revision Date: 06.04.2024	SDS Nu 9374193	ımber: 3-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
	- repeated exposur		prolonged	or repeated exposure.
-	oonents:	ee agi	protonges	
	ectin:			
	et Organs	· Cen	tral nervous	s system
	ssment	: Cau		e to organs through prolonged or repeated
2,6-D	i-tert-butyl-p-cresol			
Asses	ssment			ealth effects observed in animals at concentra /kg bw or less.
Repe	ated dose toxicity			
<u>Comp</u>	oonents:			
lverm	ectin:			
Speci		: Dog		
NOAE LOAE			mg/kg Ig/kg	
	cation Route	: Oral		
	sure time		Veeks	
	et Organs		tral nervous	
Symp	toms	: Dilat	tation of the	e pupil, Tremors, Lack of coordination, anorex
Speci	es	: Mon	key	
NOAE	EL	: 1.2 r	mg/kg	
	cation Route	: Oral		
Expos	sure time		eeks significant a	dverse effects were reported
Reme		. 110 0	ignineant a	
Speci		: Rat		
NOAE LOAE			mg/kg	
	cation Route	: 0.8	mg/kg	
	sure time		onths	
Targe	et Organs	: sple	en, Bone m	narrow, Kidney
2,6-D	i-tert-butyl-p-cresol			
Speci		: Rat		
NOAE			ng/kg	
	cation Route sure time		estion Aonths	
Expos		. 22 N	1011115	

### Aspiration toxicity

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.3	06.04.2024	9374193-00013	Date of first issue: 27.08.2021

### Experience with human exposure

### Components:

### Ivermectin:

Skin contact Eye contact Ingestion	<ul> <li>Remarks: Can be absorbed through skin.</li> <li>Remarks: May irritate eyes.</li> <li>Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom- iting, apprexia, Lack of coordination</li> </ul>
	iting, anorexia, Lack of coordination
Eye contact	: Remarks: May irritate eyes.

### **SECTION 12: Ecological information**

### 12.1 Toxicity

Components:		
Ivermectin:		
Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h
		LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.000025 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic tox- icity)	:	10,000
M-Factor (Chronic aquatic toxicity)	:	10,000
2,6-Di-tert-butyl-p-cresol:		
Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 0.57 mg/l Exposure time: 96 h Method: Directive 67/548/EEC, Annex V, C.1.
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.48 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Vers 5.3	Version Revision Date: 5.3 06.04.2024		SDS Number: 9374193-00013		Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
				Exposure time: 72 Method: OECD Te	
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
	M-Facto icity)	or (Acute aquatic tox-	:	1	
	Toxicity	to microorganisms	:	EC50 : > 10,000 r Exposure time: 3 Method: OECD Te	h
	Toxicity icity)	v to fish (Chronic tox-	:	NOEC: 0.053 mg/ Exposure time: 30 Species: Oryzias Method: OECD To	) d latipes (Japanese medaka)
		v to daphnia and other invertebrates (Chron- ity)	:	Exposure time: 21	
	M-Factor toxicity	or (Chronic aquatic )	:	1	
12.2	Persis	tence and degradabil	ity		
	<u>Compo</u>	onents:			
	lverme				
	Biodeg	radability	:	Result: Not readily Biodegradation: 5 Exposure time: 24	50 %
	2,6-Di-1	tert-butyl-p-cresol:			
	Biodeg	radability	:	Result: Not readily Biodegradation: 4 Exposure time: 28 Method: OECD To	4.5 %
12.3	Bioaco	umulative potential			
	Compo	onents:			
	lverme	ctin:			
	Bioaccu	umulation	:	Bioconcentration	factor (BCF): 74
	Partitio octanol	n coefficient: n- /water	:	log Pow: 3.22	
	2,6-Di-1	tert-butyl-p-cresol:			

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024	-	DS Number: 374193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021			
Bioaccumulation		:	Species: Cyprinus carpio (Carp) Bioconcentration factor (BCF): 330 - 1,800				
	ition coefficient: n- nol/water	:	: log Pow: 5.1				
	<b>ility in soil</b> lata available						
12.5 Res	ults of PBT and vPvB a	sse	ssment				
Proc	duct:						
Assessment		:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.				
12.6 Oth	er adverse effects						
	duct: ocrine disrupting poten-	:	ered to have end	nixture does not contain components consid- ocrine disrupting properties for environment REACH Article 57(f).			
SECTIO	SECTION 13: Disposal considerations						

### 13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

14.1 UN number	
----------------	--

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
ΙΑΤΑ	:	UN 3082

### 14.2 UN proper shipping name

: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 5.3	Revision Date: 06.04.2024		OS Number: 74193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
			N.O.S. (Ivermectin)	
ADF	8	:	ENVIRONMENTA N.O.S. (Ivermectin)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
RID		:	ENVIRONMENTA N.O.S. (Ivermectin)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
IMD	G	:	ENVIRONMENT N.O.S. (Ivermectin)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
ΙΑΤΑ	A	:	Environmentally h (Ivermectin)	nazardous substance, liquid, n.o.s.
14.3 Trar	nsport hazard class(es)			
			Class	Subsidiary risks
ADN	1	:	9	
ADR	R	:	9	
RID		:	9	
IMD	G	:	9	
IATA	A	:	9	
14.4 Pac	king group			
Clas	king group sification Code ard Identification Number	:	III M6 90 9	
Clas Haza Labe	king group sification Code ard Identification Number		III M6 90 9 (-)	
<b>RID</b> Pack Clas	king group sification Code ard Identification Number	:	III M6 90 9	
Labe	king group	:	III 9 F-A, S-F	
	A (Cargo) king instruction (cargo	:	964	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Versio 5.3	on	Revision Date: 06.04.2024		DS Number: 374193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
F		) g instruction (LQ) g group	:	Y964 III Miscellaneous	
F G F F	Packing ger airc Packing	Passenger) g instruction (passen- craft) g instruction (LQ) g group	:	964 Y964 III Miscellaneous	
14.5 E	Enviro	nmental hazards			
E	<b>ADN</b> Enviror <b>ADR</b>	mentally hazardous	:	yes	
		mentally hazardous	:	yes	
	<b>RID</b> Enviror	mentally hazardous	:	yes	
	<b>MDG</b> Marine	pollutant	:	yes	
	•	Passenger)	:	yes	
		Cargo) Imentally hazardous	:	yes	
	•	I precautions for use			

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)

: Conditions of restriction for the following entries should be considered: Number on list 3 Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024	SDS Number: 9374193-00013		f last issue: 30.09. f first issue: 27.08.	
					her an entry is appli- ing on the market or
		f substances of very hig	lh :	Not applicable	
The P		utants Regulations (reta as amended for Great E		Not applicable	
Regul	lation (EC) No 1005/20 the ozone layer	009 on substances that	de- :	Not applicable	
ÜK RI	•	es subject to authorisat	ion :	Not applicable	
GB E	,	zardous chemicals - Prio	or :	Not applicable	
		azards Regulations 201	5 (COMA	AH)	
	,	Ū	,	Quantity 1	Quantity 2
E1		ENVIRONMENT. HAZARDS	AL	100 t	200 t

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
		lines.

#### Full text of H-Statements

H300	:	Fatal if swallowed.
H311	:	Toxic in contact with skin.
H370	:	Causes damage to organs if swallowed.
H372	:	Causes damage to organs through prolonged or repeated
		exposure if swallowed.
H400	:	Very toxic to aquatic life.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024	SDS Number: 9374193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
H410		: Very toxic to	aquatic life with long lasting effects.
Full t	ext of other abbrevia	tions	
Acute		: Acute toxicity	
	tic Acute		cute) aquatic hazard
	tic Chronic	<b>č</b> (	nronic) aquatic hazard
STOT	Γ RE		et organ toxicity - repeated exposure
STOT	T SE	: Specific targe	et organ toxicity - single exposure
GB E	H40	: UK. EH40 WI	EL - Workplace Exposure Limits
GB E	H40 / TWA	: Long-term ex	posure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified: NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
---	---	--

Classification of the mixture:		Classification procedure:
Acute Tox. 4	H302	Calculation method
STOT SE 2	H371	Calculation method

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Ivermectin (3.5%) Formulation

Version 5.3	Revision Date: 06.04.2024	SDS Number: 9374193-00013	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
STOT	RE 2	H373	Calculation method	
Aquati	ic Acute 1	H400	Calculation method	
Aquati	ic Chronic 1	H410	Calculation method	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN